| Hazard Information | Back Directory | [Uses]
Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine tartrate reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine tartrate improves cognitive performance and attenuates the progression of Alzheimer's disease[1][2][3]. | [in vivo]
Phenserine (1-4 mg/kg; intraperitoneal injection; for 4 days; male Fischer-344 rats) treatment improves learning when cholinergic function has been impaired in a spatial memory task[3]. | Animal Model: | Male Fischer-344 rats (5 months old) induced by scopolamine[3] | | Dosage: | 1 mg/kg, 2 mg/kg, 4 mg/kg | | Administration: | Intraperitoneal injection; for 4 days | | Result: | Improved morris water maze performance of scopolamine-treated rats. |
| [References]
[1] Klein J. Phenserine. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. DOI:10.1517/13543784.16.7.1087
[2] Asuni AA, et al. Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. Ann Neurol. 2014 May;75(5):684-99. DOI:10.1002/ana.24149
[3] https://www.ncbi.nlm.nih.gov/pubmed/24687915 DOI:10.1016/j.lfs.2004.06.028 |
|
|